瑞德西韦和法匹拉韦治疗 COVID-19 的心血管注意事项。
Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
机构信息
Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
出版信息
Cardiovasc Hematol Disord Drug Targets. 2021;21(2):88-90. doi: 10.2174/1871529X21666210812103535.
After the outbreak of COVID-19, many novel drugs have been introduced to improve patients' conditions. Remdesivir and Favipiravir are among the most common drugs used against SARS-CoV-2. Although promising, cardiovascular side effects of these drugs should be considered by physicians and nurses. In this study, we searched databases for assessing the cardiovascular side effects of Remdesivir and Favipiravir. It seems that despite the beneficial effects of these drugs, due to the cardiovascular complications of COVID-19 and cardiovascular side effects of these drugs, which can overlap with each other, the use of these drugs can be a challenging issue in the cardiovascular practice.
COVID-19 爆发后，引入了许多新型药物来改善患者的病情。瑞德西韦和法匹拉韦是最常用于对抗 SARS-CoV-2 的药物之一。尽管这些药物有一定的前景，但医生和护士应该考虑这些药物的心血管副作用。在这项研究中，我们检索了数据库以评估瑞德西韦和法匹拉韦的心血管副作用。尽管这些药物有一定的益处，但由于 COVID-19 的心血管并发症以及这些药物的心血管副作用可能相互重叠，因此在心血管实践中使用这些药物可能是一个具有挑战性的问题。
Zotero 插件